Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains

Bromodomains (BD) are readers of lysine acetylation marks present in numerous proteins associated with chromatin. Here we describe a dual inhibitor of the bromodomain and PHD finger (BRPF) family member BRPF2 and the TATA box binding protein-associated factors TAF1 and TAF1L. These proteins are found in large chromatin complexes and play important roles in transcription regulation. The substituted benzoisoquinolinedione series was identified by high-throughput screening, and subsequent structure–activity relationship optimization allowed generation of low nanomolar BRPF2 BD inhibitors with strong selectivity against BRPF1 and BRPF3 BDs. In addition, a strong inhibition of TAF1/TAF1L BD2 was measured for most derivatives. The best compound of the series was BAY-299, which is a very potent, dual inhibitor with an IC50 of 67 nM for BRPF2 BD, 8 nM for TAF1 BD2, and 106 nM for TAF1L BD2. Importantly, no activity was measured for BRD4 BDs. Furthermore, cellular activity was evidenced using a BRPF2– or TAF1–histone H3.3 or H4 interaction assay.

[1]  S. Knapp,et al.  Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies. , 2017, Journal of medicinal chemistry.

[2]  Karen E Gascoigne,et al.  Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. , 2016, Journal of medicinal chemistry.

[3]  S. Knapp,et al.  Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.

[4]  C. Arrowsmith,et al.  Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. , 2016, Journal of medicinal chemistry.

[5]  Vassilios Myrianthopoulos,et al.  Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis , 2016, Journal of medicinal chemistry.

[6]  R. Prinjha,et al.  Clinical progress and pharmacology of small molecule bromodomain inhibitors. , 2016, Current opinion in chemical biology.

[7]  Min Seong Kim,et al.  The BRPF2/BRD1-MOZ complex is involved in retinoic acid-induced differentiation of embryonic stem cells. , 2016, Experimental cell research.

[8]  Christoph Bock,et al.  Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. , 2016, Nature chemical biology.

[9]  Andrew C Good,et al.  Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. , 2016, Journal of medicinal chemistry.

[10]  David J. Fallon,et al.  GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain , 2016, ACS medicinal chemistry letters.

[11]  C. Petosa,et al.  Bromodomains: Structure, function and pharmacology of inhibition. , 2016, Biochemical pharmacology.

[12]  Clara D. Christ,et al.  Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2 , 2016, Journal of medicinal chemistry.

[13]  E. Nogales,et al.  Structure of promoter-bound TFIID and insight into human PIC assembly , 2016, Nature.

[14]  Kyle V. Butler,et al.  A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. , 2016, ACS chemical biology.

[15]  F. A. Romero,et al.  Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.

[16]  Andrew J. Bannister,et al.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.

[17]  S. Knapp,et al.  Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor , 2016, Journal of medicinal chemistry.

[18]  G. Poncet-Montange,et al.  Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. , 2016, Journal of medicinal chemistry.

[19]  R. Shamir,et al.  Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism , 2016, Cellular and Molecular Life Sciences.

[20]  B. Haendler,et al.  Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs , 2016, Expert opinion on therapeutic targets.

[21]  Jennifer L. Knight,et al.  OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. , 2016, Journal of chemical theory and computation.

[22]  Xiang-Jiao Yang,et al.  The Chromatin Regulator BRPF3 Preferentially Activates the HBO1 Acetyltransferase but Is Dispensable for Mouse Development and Survival* , 2015, The Journal of Biological Chemistry.

[23]  Edward Yang,et al.  TAF1 Variants Are Associated with Dysmorphic Features, Intellectual Disability, and Neurological Manifestations , 2015, American journal of human genetics.

[24]  Susanne Müller,et al.  Open access chemical probes for epigenetic targets , 2015, Future medicinal chemistry.

[25]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[26]  Marie Jung,et al.  Targeting BET bromodomains for cancer treatment. , 2015, Epigenomics.

[27]  K. Wood,et al.  NanoBRET--A Novel BRET Platform for the Analysis of Protein-Protein Interactions. , 2015, ACS chemical biology.

[28]  S. Knapp,et al.  Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF , 2015, Journal of medicinal chemistry.

[29]  J. Kinney,et al.  Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.

[30]  E. Wang,et al.  The Chromatin Regulator Brpf1 Regulates Embryo Development and Cell Proliferation* , 2015, The Journal of Biological Chemistry.

[31]  Andreas H. Göller,et al.  Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology To Improve in Silico pKa Prediction , 2015, J. Chem. Inf. Model..

[32]  Wei Zhang,et al.  Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors , 2014, Journal of medicinal chemistry.

[33]  David J. Fallon,et al.  1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. , 2014, ACS medicinal chemistry letters.

[34]  Junwei Shi,et al.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition. , 2014, Molecular cell.

[35]  Nicola J. Richmond,et al.  Validity of ligand efficiency metrics. , 2014, ACS medicinal chemistry letters.

[36]  S. Knapp,et al.  Targeting bromodomains: epigenetic readers of lysine acetylation , 2014, Nature Reviews Drug Discovery.

[37]  S. Müller,et al.  Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1 , 2014, The Journal of Biological Chemistry.

[38]  K. Gupta,et al.  More pieces to the puzzle: recent structural insights into class II transcription initiation. , 2014, Current opinion in structural biology.

[39]  Xiang-Jiao Yang,et al.  Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes , 2014, Epigenetics.

[40]  P. Sandy,et al.  Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. , 2013, ACS medicinal chemistry letters.

[41]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[42]  S. Knapp,et al.  Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands , 2013, Journal of medicinal chemistry.

[43]  S. Dusuel,et al.  Topological phase transitions in the golden string-net model. , 2012, Physical review letters.

[44]  S. Knapp,et al.  Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit , 2012, Journal of medicinal chemistry.

[45]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[46]  David M. Wilson,et al.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.

[47]  S. Hatakeyama,et al.  TRIM proteins and cancer , 2011, Nature Reviews Cancer.

[48]  S. Knapp,et al.  Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. , 2011, Molecular bioSystems.

[49]  O. Hucke,et al.  Assessing atropisomer axial chirality in drug discovery and development. , 2011, Journal of medicinal chemistry.

[50]  A. Iwama,et al.  The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. , 2011, Blood.

[51]  Stefan Knapp,et al.  Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.

[52]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[53]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[54]  O. Hucke,et al.  Revealing Atropisomer Axial Chirality in Drug Discovery , 2011, ChemMedChem.

[55]  G. Bringmann,et al.  Atroposelective total synthesis of axially chiral biaryl natural products. , 2011, Chemical reviews.

[56]  Vincent B. Chen,et al.  MolProbity: all-atom structure validation for macromolecular crystallography , 2009, Acta crystallographica. Section D, Biological crystallography.

[57]  S. LaPlante,et al.  The challenge of atropisomerism in drug discovery. , 2009, Angewandte Chemie.

[58]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[59]  M. Ōki Recent Advances in Atropisomerism , 2007 .

[60]  D. Page,et al.  Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis. , 2002, Human molecular genetics.

[61]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[62]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[63]  M. A. Patrick,et al.  A comprehensive method for determining hydrophobicity constants by reversed-phase high-performance liquid chromatography. , 1988, Journal of medicinal chemistry.

[64]  H. Shimada,et al.  Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ–TIF2 fusion , 2013, International Journal of Hematology.

[65]  Stefan Knapp,et al.  Kinase inhibitor selectivity profiling using differential scanning fluorimetry. , 2012, Methods in molecular biology.

[66]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[67]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[68]  Serge X. Cohen,et al.  Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 , 2008, Nature Protocols.

[69]  Ballard,et al.  Overview of the CCP 4 suite and current developments , 2022 .